DR. LUIS MADERO

RESEARCH

Dr. Luis Madero
leads cancer research at
Children’s University Hospital “Niño Jesús”, Madrid

University Hospital “Niño Jesús” is a national and international reference center for the diagnosis and treatment of children with cancer. Some of the research areas include childhood leukemia, cell and oncolytic immunotherapy for metastatic or refractory pediatric tumors, physical exercise in children with cancer, cell therapy with mesenchymal cells, and the development of new targeted therapies.

These translational research projects are funded by competitive national and international grants. Over the last ten years, a steady level of scientific output and funding has been maintained.

RESEARCH
AREAS
RESEARCH
PROJECTS
CLINICAL
TRIALS
3
Play Video
DR. LUIS MADERO

RESEARCH
AND CHILDHOOD
LEUKEMIA

RESEARCH

AREAS

CHILDHOOD ACUTE LEUKEMIA:

  • Molecular diagnosis of minimal residual disease
  • Cell adhesion molecules, cell migration pathways and clinical relevance (1)
  • Identifying and validating relapse biomarkers for acute lymphoblastic leukemia (2)
(1) Research area funded by    
(2) Research area funded by

NEW THERAPIES FOR PEDIATRIC SOLID TUMORS

  • Cell-delivered oncolytic gene therapy (1)
  • Clinical trial to study a novel oncolytic cell therapy for metastatic or refractory pediatric tumors
  • Clinical trial to study the feasibility of combining oncolytic virus therapy with standard treatment in children and adolescents with metastatic sarcoma (1)
  • Clinical trial to study the use of ICOVIR-5 in refractory central nervous system tumors
(1) Research area funded by

UMBILICAL CORD MESENCHYMAL STEM CELL THERAPIES

  • Mesenchymal stem cell therapy in Pediatrics
  • Cerebral palsy in childhood
  • Graft versus host disease
  • Osteonecrosis in patients with cancer
Research area funded by    biocord   sevibe

CANCER AND PHYSICAL EXERCISE

  • Physical exercise to improve the performance status of children with cancer
  • Impact of physical exercise in patients with graft versus host disease
Research area funded by    universidad europea   fundación aladina

IMMUNOTHERAPIES FOR THE TREATMENT OF PEDIATRIC SARCOMA

  • Study about the role of immunoediting in sarcomas
  • Analysis of the immune infiltration in pediatric sarcomas
  • Combination of immunotherapies (1)
(1) Research area funded by

TUMOR STEM CELLS IN PEDIATRIC SARCOMA

  • Origin of pediatric bone tumors
  • Cell subpopulation dynamics in pediatric sarcoma

Peripheral blood human mesenchymal stem cells: Mobilization, isolation and novel biomarkers.

Funding: “Fondo de Investigaciones Sanitarias”. File Nr. FIS PI052217

Role: Sub-investigator

Date: 2006-2008

Diagnosis of meningeal infiltration in children with acute lymphoblastic leukemia.

  • Funding: “Inocente” Foundation
  • Role: Principal investigator
  • Date: 2007-2009

Fancogene: Use of molecular biology to develop more efficient diagnostic and therapeutic tools for patients with Fanconi anemia/BRCA genomes.

  • Funding: “Genoma” Foundation
  • Role: Principal investigator
  • Date: 2007-2010

Celyvir: Oncolytic cell therapy for metastatic neuroblastoma.

  • Funding: “Fondo de Investigaciones Sanitarias”. File Nr. ECO7/90591
  • Role: Sub-investigator
  • Date: 2008-2010

ICOVIR-5 in the treatment of relapsed or refractory pediatric central nervous system tumors

  • Funding: “Fondo de Investigaciones Sanitarias”. File Nr. ECO8/00094
  • Role: Principal investigator
  • Date: 2009-2011

Production and differentiation of induced pluripotent stem cells (iPS) of patients with genetic diseases of the immune-hematopoietic system

  • Funding: “Ministerio de Ciencia e Innovación”. File Nr. PLE 2009-0100.
  • Role: Sub-investigator
  • Date: 2010-2012

Diagnosis of meningeal infiltration in children with central nervous system tumors

  • Funding: “Fondo de Investigaciones Sanitarias”. File Nr. PI 10/02811.
  • Role: Principal investigator
  • Date: 2010-2012

Making medicines out of stem cells: Allogenic ACS and bioengineering for clinical use

  • Funding: “Ministerio de Ciencias e Innovación”
  • Role: Sub-investigator
  • Date: 2010-2012

Identifying and validating biomarkers for relapsed childhood acute lymphoblastic leukemia

  • Funding: “Fondo de Investigaciones Sanitarias.” File Nr. PI13/02475.
  • Role: Principal investigator
  • Date: 2014-2016.

Development of novel targeted therapies for neuroblastoma.

  • Funding: “Inocente” Foundation
  • Role: Sub-investigator
  • Date: 2015-2016.

RESEARCH

PROJECTS

CLINICAL

TRIALS

LEUKEMIA AND LYMPHOMA

Drug name: CARFILZOMIB

Mechanism of action: Proteasome inhibitor

Trial phase: I-II

Study population: Patients with relapsed precursor B-cell and T-cell ALL, and T-cell lymphoblastic lymphoma

Nr.: 2014-001633-84

Drug name: IBRUTINIB

Mechanism of action: Tyrosine-kinase inhibitor

Trial phase: II

Study population: Mature B-cell lymphoma at first relapse, in combination with “RICE” chemotherapy

Nr.: 2016-000259-28

Drug name: NIVOLUMAB + BRENTUXIMAB

Mechanism of action: anti-PD1 and anti-CD34

Trial phase: II

Study population: Non-Hodgkin lymphoma at first relpase

Nr.: 02927769

Drug name: BLINATUMOMAB

Mechanism of action: Anti-CD19

Trial phase: III

Study population: Precursor B-cell ALL at first high-risk relapse

Nr.: 2014-002476-92

SOLID TUMORS

Drug name: REGORAFENIB

Mechanism of action: Multi tyrosine-kinase inhibitor + Vincristine and Irinotecan

Trial phase: I

Study population: Relapsed/refractory solid tumors

Nr.: 2013-003579-36

Drug name: T-VEC

Mechanism of action: Oncolytic virus

Trial phase: I

Study population: Relapsed/refractory extracranial solid tumors, accessible for direct therapeutic injection

Nr.: 2015-003645-25

Drug name: DABRAFENIB

Mechanism of action: BRAF inhibitor

Trial phase: I-II

Study population: Relapsed/refractory high grade glioma, melanoma or thyroid cancer

Nr.: 2012-001499-12

Drug name: COBIMETINIB

Mechanism of action: MEK inhibitor

Trial phase: I-II

Study population: Relapsed or refractory solid tumors (glioma, DIPG, rhabdomyosarcoma, neuroblastoma, melanoma, rhabdoid tumors, NF-1 linked tumors and other tumors with RAS/RAF/MEK/ERK activity).

Nr.: 2014-004685-25

Drug name: ABRAXANE

Mechanism of action: Nab-paclitaxel

Trial phase: II

Study population:

First cohort: Relapsed/refractory desmoid tumors

Second cohort: Relapsed/refractory Ewing sarcoma

Relpased/refractory desmoplastic small-round-cell tumors

Nr.: 2013-000144-26

Drug name: PAZOPANIB

Mechanism of action: VEGF inhibitor

Trial phase: II

Study population: Refractory solid tumors (rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Ewing/PNET sarcoma, osteosarcoma, neuroblastoma, hepatoblastoma)

Nr.: 2013-003595-12

Drug name: BEACON

Mechanism of action: VEGFR inhibitor +/-:

Temozolomide

Irinotecan-temozolomide

Topotecan-temozolomide

Trial phase: II

Study population: Relapsed/refractory neuroblastoma

Nr.: 2012-000072-42

Drug name: LENVATINIB

Mechanism of action: VEGFR inhibitor as single treatment or in combination with ifosfamide + etoposide

Trial phase: I-II

Study population: Relapsed/refractory osteosarcoma and differentiated thyroid cancer

Nr.: 2013-005534-38

Drug name: NIVOLUMAB +/- IPILIMUMAB

Mechanism of action: Anti-PD1 and anti-CTLA4 immunotherapy

Trial phase: II

Study population: CNS tumors (DIPG, medulloblastoma, ependymoma, high grade glioma and other high grade CNS tumors)

Nr.: 2016-004441-82

Drug name: POMALIDOMIDE

Mechanism of action: Immunomodulation and anti-angiogenesis

Trial phase: II

Study population: Pediatric patients with CNS tumors (DIPG, medulloblastoma, ependymoma and high grade glioma)

Nr.: 2016-002903-25

Drug name: M14-483 EGFR ANTIBODY DRUG CONJUGATE ABVIE

Mechanism of action: EGFR inhibitor

Trial phase: II

Study population: CNS tumors with EGFR amplification (high grade glioma, DIPG); single therapy or in combination with temozolomide.

Nr.: 2014-004438-24